- Company
- Vyndamax may be prescribed at tertiary hospitals in KOR
- by Eo, Yun-Ho Apr 16, 2025 05:55am
- Vyndamax, which was finally granted insurance reimbursement after 5 attempts, may now be prescribed in general hospitals. According to industry sources, Pfizer Korea's treatment for ATTR-CM (Tafamidis 61mg) passed the drug committees of 26 medical institutions nationwide, including the ‘Big 5’ major hospitals (Samsung Medical Center, Se
- Opinion
- [Reporter's View] The MOHW’s contradiction
- by Lee, Jeong-Hwan Apr 16, 2025 05:55am
- The Ministry of Health and Welfare cited the 'non-face-to-face medical treatment pilot project' as an excellent administrative example last year. The reason for its excellence is that the non-face-to-face treatment, which was urgently and temporarily permitted in February 2020 in response to the COVID-19 pandemic, was converted into a pilot
- Company
- Tepmetko targets rare lung cancer target with reimbursement
- by Whang, byung-woo Apr 16, 2025 05:55am
- Merck is seeking to increase the market influence of Tepmetko (tepotinib), which was granted reimbursement 3 years after its approval, by improving treatment access. Although the MET mutation is a rare mutation that occurs in 1.8-3.1% of non-small cell lung cancer patients in Korea, it is evaluated that the drug’s reimbursement will have a s
- Policy
- Will a 'Duodart' generic for prostatate drug be available?
- by Lee, Hye-Kyung Apr 16, 2025 05:55am
- A generic version of GSK's benign prostatic hyperplasia (BPH) combination product 'Duodart Capsule (dutasteride·tamsulosin hydrochloride),' which drove the success of the combination drug market for urology in Korea, is now under development. On the 14th, the Ministry of Food and Drug Safety (MFDS) approved an open-label, randomized, two
- Policy
- Global pharma proposes 'indication-based pricing system'
- by Lee, Jeong-Hwan Apr 16, 2025 05:55am
- Overseas global pharmaceutical companies with subsidiaries in Korea are currently voicing the adoption of policies aimed at resolving 'reimbursement inequities' for therapies for severe and rare diseases and implementing an 'indication-based pricing system' amid an early presidential election. While the Korean government maintains that an
- Company
- Orphan drug 'Thio Spal-P' avoids approval cancellation
- by Kim, Jin-Gu Apr 15, 2025 05:55am
- A rare disease treatment, 'Thio Spal-P Inj (thiotepa),' faced narrow escape from receiving approval cancellation. According to pharmaceutical industry sources on the 11th, the Seoul Administrative Court ruled in favor of Dongin Pharm against the Ministry of Food and Drug Safety (MFDS), ruling a 'plaintiff victory' on the 10th. Dongin P
- Company
- Daehwa Pharmaceutical's Liporaxel aims for listing in China
- by Nho, Byung Chul Apr 15, 2025 05:55am
- The world's first oral paclitaxel, Liporaxel, for gastric cancer, is expected to enter the first negotiation step with the Chinese health authority in June for health insurance listing. The negotiation outcome gains attention. Daehwa Pharmaceutical's Liporaxel is sold in local Chinese hospitals at approximately KRW 940,000 per 30&8239;mg
- Company
- BD experts in demand due to increasing global partnerships
- by Whang, byung-woo Apr 15, 2025 05:54am
- Due to increasing technology transfer and partnership opportunities in the pharmaceutical and biotech industries, the role of business development (BD) is becoming increasingly important. Also, demand is growing for the ability to move beyond R&D that advances science-based technologies to securing actual deals. BD is a position that i
- Policy
- DPK’s election pledge includes substitution dispensing
- by Lee, Jeong-Hwan Apr 15, 2025 05:54am
- The Democratic Party of Korea will include a policy to support domestically developed new drugs through a drug pricing system that links the investment rate (amount) of research and development (R&D) by pharmaceutical companies with a drug’s insurance price ceiling and drug price reduction rate in its presidential election pledge. DPK’s
- Policy
- NHIS prepares measures to implement dual drug pricing system
- by Lee, Tak-Sun Apr 15, 2025 05:54am
- The National Health Insurance Service (NHIS) is preparing a procedure for implementing the dual drug pricing system for domestically developed new drugs and will collect industry opinion this month. The measure seeks to prepare guidelines for actual negotiations, as the MOHW's notification last month included a provision for the dual d
